Kailing Chemical

Kailing Pharmaceutical is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology. The company focuses on addressing unmet medical needs in cancer treatment, particularly targeting resistance mechanisms in lung cancer and other solid tumors. Its lead program, KL-001, is a potent, next-generation inhibitor of Anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1), designed to provide therapeutic options for patients with non-small cell lung cancer (NSCLC). Kailing Pharmaceutical operates out of the Suzhou Biobay industrial park and has established a robust research platform supported by a team of experienced scientists from global pharmaceutical backgrounds. The company's pipeline includes several other targeted therapies in various stages of pre-clinical development.